-
1
-
-
33748041958
-
Effect of protein aggregates: An immunologic perspective
-
Rosenberg AS. 2006. Effect of protein aggregates: An immunologic perspective. AAPS J 8:E501-E507.
-
(2006)
AAPS J
, vol.8
-
-
Rosenberg, A.S.1
-
2
-
-
68949085124
-
Protein aggregation: Pathways, induction factors and analysis
-
Mahler H-C, Freiss W, Grauschopf U, Keise S. 2009. Protein aggregation: Pathways, induction factors and analysis. J Pharm Sci 98:2909-2934.
-
(2009)
J Pharm Sci
, vol.98
, pp. 2909-2934
-
-
Mahler, H.-C.1
Freiss, W.2
Grauschopf, U.3
Keise, S.4
-
3
-
-
33748742268
-
Is any measurement method optimal for all aggregate sizes and types?
-
Philo JS. 2006. Is any measurement method optimal for all aggregate sizes and types? AAPS J 8:E564-E571.
-
(2006)
AAPS J
, vol.8
-
-
Philo, J.S.1
-
4
-
-
69249206868
-
A critical review of methods for size characterization of non-particulate protein aggregates
-
Philo JS. 2009. A critical review of methods for size characterization of non-particulate protein aggregates. Curr Pharm Biotechnol 10:359-372.
-
(2009)
Curr Pharm Biotechnol
, vol.10
, pp. 359-372
-
-
Philo, J.S.1
-
5
-
-
55849153131
-
Protein particulate issues in biologics development
-
Das T, Nema S. 2008. Protein particulate issues in biologics development. Am Pharm Rev 11(4):52-57.
-
(2008)
Am Pharm Rev
, vol.11
, Issue.4
, pp. 52-57
-
-
Das, T.1
Nema, S.2
-
6
-
-
69249215475
-
A critical review of analytical methods for subvisible and visible particles
-
Narhi LO, Jiang Y, Cao S, Benedek K, Shnek D. 2009. A critical review of analytical methods for subvisible and visible particles. Curr Pharm Biotechnol 10:378-381.
-
(2009)
Curr Pharm Biotechnol
, vol.10
, pp. 378-381
-
-
Narhi, L.O.1
Jiang, Y.2
Cao, S.3
Benedek, K.4
Shnek, D.5
-
7
-
-
62749099087
-
Overlooking subvisible particles in therapeutic protein products: Gaps that may compromise product quality
-
Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJA, Middaugh CR, Winter G, Fan YX, Kirshner S, Verthelyi D, Kozlowski S, Clouse KA, Swann PG, Rosenberg A, Cherney B. 2009. Overlooking subvisible particles in therapeutic protein products: Gaps that may compromise product quality. J Pharm Sci 98:1202-1205.
-
(2009)
J Pharm Sci
, vol.98
, pp. 1202-1205
-
-
Carpenter, J.F.1
Randolph, T.W.2
Jiskoot, W.3
Crommelin, D.J.A.4
Middaugh, C.R.5
Winter, G.6
Fan, Y.X.7
Kirshner, S.8
Verthelyi, D.9
Kozlowski, S.10
Clouse, K.A.11
Swann, P.G.12
Rosenberg, A.13
Cherney, B.14
-
8
-
-
0033376410
-
The scientific basis for visible particle inspection
-
Knapp JZ. 1999. The scientific basis for visible particle inspection. PDA J Pharm Sci Tech 53:291-302.
-
(1999)
PDA J Pharm Sci Tech
, vol.53
, pp. 291-302
-
-
Knapp, J.Z.1
-
9
-
-
10944231251
-
A risk-based approach to immunogenicity concerns of therapeutic protein products. Part II: Considering host-specific and product-specific factors impacting immunogenicity
-
Rosenberg AS, Worobec A. 2004. A risk-based approach to immunogenicity concerns of therapeutic protein products. Part II: Considering host-specific and product-specific factors impacting immunogenicity. BioPharm Int 17(12):34-42.
-
(2004)
BioPharm Int
, vol.17
, Issue.12
, pp. 34-42
-
-
Rosenberg, A.S.1
Worobec, A.2
-
10
-
-
32944459736
-
Factors influencing the immunogenicity of therapeutic proteins
-
Schellekens H. 2005. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant 20:vi3-vi9.
-
(2005)
Nephrol Dial Transplant
, vol.20
-
-
Schellekens, H.1
-
11
-
-
0030856842
-
Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-a) in normal and transgenic mice
-
DOI 10.1023/A:1012193326789
-
Braun A, Kwee L, Labow MA, Alsenz J. 1997. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of Interferon alpha (IFN-a) in normal and transgenic mice. Pharm Res 14:1472-1478. (Pubitemid 27481082)
-
(1997)
Pharmaceutical Research
, vol.14
, Issue.10
, pp. 1472-1478
-
-
Braun, A.1
Kwee, L.2
Labow, M.A.3
Alsenz, J.4
-
12
-
-
21244436416
-
Development of a transgenic mouse model immune tolerant for human Interferon beta
-
Hermeling S, Jiskoot W, Crommelin DJA, Bornaes C, Schellekens H. 2005. Development of a transgenic mouse model immune tolerant for human Interferon beta. Pharm Res 22:847-851.
-
(2005)
Pharm Res
, vol.22
, pp. 847-851
-
-
Hermeling, S.1
Jiskoot, W.2
Crommelin, D.J.A.3
Bornaes, C.4
Schellekens, H.5
-
13
-
-
33646546740
-
Antibody response to aggregated human Interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation
-
Hermeling S, Schellekens H, Maas C, Gebbink MFBG, Crommelin DJA, Jiskoot W. 2006. Antibody response to aggregated human Interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J Pharm Sci 95:1084-1096.
-
(2006)
J Pharm Sci
, vol.95
, pp. 1084-1096
-
-
Hermeling, S.1
Schellekens, H.2
Maas, C.3
Gebbink, M.F.B.G.4
Crommelin, D.J.A.5
Jiskoot, W.6
-
14
-
-
32644434554
-
Influence of aggregation on immunogenicity of recombinant human factor VIII in hemophilia a mice
-
DOI 10.1002/jps.20529
-
Purohit VS, Middaugh CR, Balasubramanian SV. 2006. Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice. J Pharm Sci 95:358-371. (Pubitemid 43241978)
-
(2006)
Journal of Pharmaceutical Sciences
, vol.95
, Issue.2
, pp. 358-371
-
-
Purohit, V.S.1
Middaugh, C.R.2
Balasubramanian, S.V.3
-
15
-
-
46149124807
-
How to predict and prevent the immunogenicity of therapeutic proteins
-
Schellekens H. 2008. How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnol Annu Rev 14:191-202.
-
(2008)
Biotechnol Annu Rev
, vol.14
, pp. 191-202
-
-
Schellekens, H.1
-
16
-
-
17644378667
-
Immunogenicity of engineered antibodies
-
Hwang WYK, Foote J. 2005. Immunogenicity of engineered antibodies. Methods 36:3-10.
-
(2005)
Methods
, vol.36
, pp. 3-10
-
-
Hwang, W.Y.K.1
Foote, J.2
-
17
-
-
55749109195
-
Shaken, not stirred - Mechanical stress testing of an IgG1 antibody
-
Kiese S, Pappenberger A, Friess W, Mahler H-C. 2008. Shaken, not stirred - Mechanical stress testing of an IgG1 antibody. J Pharm Sci 97:4347-4366.
-
(2008)
J Pharm Sci
, vol.97
, pp. 4347-4366
-
-
Kiese, S.1
Pappenberger, A.2
Friess, W.3
Mahler, H.-C.4
-
18
-
-
68949135230
-
Immunogenicity of aggregates of recombinant human growth hormone in mouse models
-
Fradkin AH, Carpenter JF, Randolph TW. 2009. Immunogenicity of aggregates of recombinant human growth hormone in mouse models. J Pharm Sci 98:3247-3264.
-
(2009)
J Pharm Sci
, vol.98
, pp. 3247-3264
-
-
Fradkin, A.H.1
Carpenter, J.F.2
Randolph, T.W.3
-
19
-
-
3843149585
-
Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans
-
Bugelski PJ, Treacy G. 2004. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. Curr Opin Mol Ther 6:10-16.
-
(2004)
Curr Opin Mol Ther
, vol.6
, pp. 10-16
-
-
Bugelski, P.J.1
Treacy, G.2
-
20
-
-
67349088299
-
How to systematically evaluate immunogenicity of therapeutic proteins - Regulatory considerations
-
10.1016/j.nbt.2009.03.012
-
Jahn E-M, Schneider C. 2009. How to systematically evaluate immunogenicity of therapeutic proteins - Regulatory considerations. New Biotechnol 25:280-286. 10.1016/j.nbt.2009.03.012.
-
(2009)
New Biotechnol
, vol.25
, pp. 280-286
-
-
Jahn, E.-M.1
Schneider, C.2
-
21
-
-
16844367771
-
A risk-based approach to immunogenicity concerns of therapeutic protein products. Part III: Effects of manufacturing changes on immunogenicity and the utility of animal immunogenicity studies
-
Rosenberg AS, Worobec A. 2005. A risk-based approach to immunogenicity concerns of therapeutic protein products. Part III: Effects of manufacturing changes on immunogenicity and the utility of animal immunogenicity studies. BioPharm Int 18(1):32-36.
-
(2005)
BioPharm Int
, vol.18
, Issue.1
, pp. 32-36
-
-
Rosenberg, A.S.1
Worobec, A.2
-
22
-
-
56949105659
-
Generic construction of single component particles that elicit humoral and cellular responses without the need for adjuvants
-
White PJ, Anastasopoulos F, Church JE, Kuo C-Y, Boyd BJ, Hickey PLC, Sze Tu L, Burns P, Lew AM, Heath WR, Davey GM, Pouton CW. 2008. Generic construction of single component particles that elicit humoral and cellular responses without the need for adjuvants. Vaccine 26:6824-6831.
-
(2008)
Vaccine
, vol.26
, pp. 6824-6831
-
-
White, P.J.1
Anastasopoulos, F.2
Church, J.E.3
Kuo, C.-Y.4
Boyd, B.J.5
Hickey, P.L.C.6
Sze Tu, L.7
Burns, P.8
Lew, A.M.9
Heath, W.R.10
Davey, G.M.11
Pouton, C.W.12
-
23
-
-
17844374154
-
Particulate contaminants of intraveneous medication and the limits set by USP General Chapter 〈788〉
-
Nath N, McNeal E, Obenhuber D, Pillari B, Shelton L, Stevens- Riley M, Sweeney N. 2004. Particulate contaminants of intraveneous medication and the limits set by USP General Chapter 〈788〉. Pharmacopeial Forum 30:2272-2280.
-
(2004)
Pharmacopeial Forum
, vol.30
, pp. 2272-2280
-
-
Nath, N.1
McNeal, E.2
Obenhuber, D.3
Pillari, B.4
Shelton, L.5
Stevens-Riley, M.6
Sweeney, N.7
-
24
-
-
69249213763
-
Separation and characterization of protein aggregates and particles by field flow fractionation
-
Cao S, Pollastrini J, Jiang Y. 2009. Separation and characterization of protein aggregates and particles by field flow fractionation. Curr Pharm Biotechnol 10:382-390.
-
(2009)
Curr Pharm Biotechnol
, vol.10
, pp. 382-390
-
-
Cao, S.1
Pollastrini, J.2
Jiang, Y.3
-
25
-
-
0023440690
-
Limitations in the use of HIAC for product particle counting
-
Chrai S, Clayton R, Mestrandrea L, Myers T, Raskin R, Sokol M, Willis C. 1987. Limitations in the use of HIAC for product particle counting. PDA J Parenteral Sci Technol 41:209-214.
-
(1987)
PDA J Parenteral Sci Technol
, vol.41
, pp. 209-214
-
-
Chrai, S.1
Clayton, R.2
Mestrandrea, L.3
Myers, T.4
Raskin, R.5
Sokol, M.6
Willis, C.7
-
26
-
-
0029387359
-
Particle size analysis. A comparative study of various methods I
-
Etzler FM, Sanderson MS. 1997. Particle size analysis. A comparative study of various methods I. Part Part Syst Charact 12:217-224.
-
(1997)
Part Part Syst Charact
, vol.12
, pp. 217-224
-
-
Etzler, F.M.1
Sanderson, M.S.2
-
27
-
-
0031375753
-
Particle size analysis. A comparative study of various methods II
-
Etzler FM, Sanderson MS. 1997. Particle size analysis. A comparative study of various methods II. Part Part Syst Charact 12:278-282.
-
(1997)
Part Part Syst Charact
, vol.12
, pp. 278-282
-
-
Etzler, F.M.1
Sanderson, M.S.2
-
28
-
-
68949132582
-
Quantitation of protein particles in parenteral solutions using Micro-Flow Imaging
-
Huang CT, Sharma D, Oma P, Krishnamurthy R. 2008. Quantitation of protein particles in parenteral solutions using Micro-Flow Imaging. J Pharm Sci 98:3058-3071.
-
(2008)
J Pharm Sci
, vol.98
, pp. 3058-3071
-
-
Huang, C.T.1
Sharma, D.2
Oma, P.3
Krishnamurthy, R.4
-
29
-
-
65349153327
-
Flow microscopy for particulate analysis in parenteral and pharmaceutical fluids
-
Sharma D, King D, Moore P, Oma P, Thomas D. 2007. Flow microscopy for particulate analysis in parenteral and pharmaceutical fluids. Eur J Parenteral Pharm Sci 12:97-101.
-
(2007)
Eur J Parenteral Pharm Sci
, vol.12
, pp. 97-101
-
-
Sharma, D.1
King, D.2
Moore, P.3
Oma, P.4
Thomas, D.5
-
30
-
-
84881026815
-
Protein aggregation and particle formation: Effects of formulation, interfaces and drug product manufacturing operations
-
in press. Wang W, Roberts C, editors. New York: John Wiley
-
Mahler H-C, Fischer S, Randolph TW, Carpenter JF. 2010 (in press). Protein aggregation and particle formation: Effects of formulation, interfaces and drug product manufacturing operations. In: Wang W, Roberts C, editors. Formulation and process development strategies for manufacturing of a biopharmaceutical. New York: John Wiley.
-
(2010)
Formulation and Process Development Strategies for Manufacturing of a Biopharmaceutical
-
-
Mahler, H.-C.1
Fischer, S.2
Randolph, T.W.3
Carpenter, J.F.4
|